Burns J W & Co. Inc. NY Has $641,000 Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Burns J W & Co. Inc. NY boosted its position in Merck & Co., Inc. (NYSE:MRK) by 2.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,613 shares of the company’s stock after buying an additional 162 shares during the quarter. Burns J W & Co. Inc. NY’s holdings in Merck & Co., Inc. were worth $641,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the stock. Murphy Capital Management Inc. raised its position in Merck & Co., Inc. by 1.5% in the 3rd quarter. Murphy Capital Management Inc. now owns 65,139 shares of the company’s stock valued at $5,483,000 after buying an additional 991 shares during the last quarter. Domani Wealth LLC increased its position in shares of Merck & Co., Inc. by 3.2% during the 3rd quarter. Domani Wealth LLC now owns 8,346 shares of the company’s stock worth $703,000 after purchasing an additional 255 shares during the last quarter. Larson Financial Group LLC increased its position in shares of Merck & Co., Inc. by 9.6% during the 3rd quarter. Larson Financial Group LLC now owns 2,867 shares of the company’s stock worth $241,000 after purchasing an additional 252 shares during the last quarter. Rockland Trust Co. increased its position in shares of Merck & Co., Inc. by 46.2% during the 3rd quarter. Rockland Trust Co. now owns 107,510 shares of the company’s stock worth $8,896,000 after purchasing an additional 33,975 shares during the last quarter. Finally, E&G Advisors LP increased its position in shares of Merck & Co., Inc. by 4.3% during the 3rd quarter. E&G Advisors LP now owns 16,841 shares of the company’s stock worth $1,418,000 after purchasing an additional 702 shares during the last quarter. 74.97% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have weighed in on MRK. Citigroup boosted their price target on Merck & Co., Inc. from $84.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, June 21st. They noted that the move was a valuation call. Societe Generale set a $105.00 price target on Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Credit Suisse Group reaffirmed a “buy” rating and set a $95.00 price target on shares of Merck & Co., Inc. in a research report on Wednesday, August 7th. JPMorgan Chase & Co. boosted their price target on Merck & Co., Inc. from $90.00 to $93.00 and gave the stock an “overweight” rating in a research report on Friday, June 14th. Finally, Leerink Swann began coverage on Merck & Co., Inc. in a research report on Thursday, August 15th. They set an “outperform” rating and a $103.00 price target on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have given a buy rating to the company. Merck & Co., Inc. has an average rating of “Buy” and a consensus price target of $93.29.

In other news, EVP Richard R. Deluca sold 6,427 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $85.09, for a total transaction of $546,873.43. Following the completion of the transaction, the executive vice president now directly owns 103,223 shares in the company, valued at approximately $8,783,245.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.27% of the company’s stock.

Shares of NYSE MRK traded up $1.07 during midday trading on Friday, hitting $84.83. 2,645,573 shares of the company’s stock were exchanged, compared to its average volume of 8,180,964. The company has a quick ratio of 0.92, a current ratio of 1.21 and a debt-to-equity ratio of 0.82. Merck & Co., Inc. has a 12 month low of $66.10 and a 12 month high of $87.35. The company’s 50 day moving average price is $84.58 and its 200 day moving average price is $82.23. The firm has a market capitalization of $213.25 billion, a PE ratio of 19.55, a price-to-earnings-growth ratio of 1.69 and a beta of 0.53.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, July 30th. The company reported $1.30 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. The company had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $10.94 billion. During the same period in the previous year, the company posted $1.06 EPS. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, equities research analysts anticipate that Merck & Co., Inc. will post 4.92 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Monday, October 7th. Stockholders of record on Monday, September 16th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, September 13th. This represents a $2.20 annualized dividend and a dividend yield of 2.59%. Merck & Co., Inc.’s dividend payout ratio is currently 50.69%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Trading Options- What is a Strangle?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.